Argos Therapeutics, Inc. Expands Global Patent Protection

Published: Sep 06, 2012

DURHAM, N.C., Sept. 6, 2012 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, announced it was recently granted two patents and one patent allowance from the United States Patent and Trademark Office (USPTO) and one patent allowance from the European Patent Office (EPO). These new patents and allowed patent applications cover compositions of matter and methods of use related to Argos' proprietary immunotherapy technologies.

Back to news